Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Long-Term Investments (2016 - 2025)

Neurocrine Biosciences' Long-Term Investments history spans 16 years, with the latest figure at $1.1 billion for Q4 2025.

  • For Q4 2025, Long-Term Investments rose 43.75% year-over-year to $1.1 billion; the TTM value through Dec 2025 reached $1.1 billion, up 43.75%, while the annual FY2025 figure was $1.1 billion, 43.75% up from the prior year.
  • Long-Term Investments reached $1.1 billion in Q4 2025 per NBIX's latest filing, up from $998.5 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $1.1 billion in Q4 2025 to a low of $244.6 million in Q1 2023.
  • Average Long-Term Investments over 5 years is $573.6 million, with a median of $550.8 million recorded in 2021.
  • Peak YoY movement for Long-Term Investments: tumbled 54.79% in 2023, then soared 186.35% in 2024.
  • A 5-year view of Long-Term Investments shows it stood at $560.7 million in 2021, then crashed by 46.6% to $299.4 million in 2022, then surged by 129.63% to $687.5 million in 2023, then rose by 7.56% to $739.5 million in 2024, then surged by 43.75% to $1.1 billion in 2025.
  • Per Business Quant, the three most recent readings for NBIX's Long-Term Investments are $1.1 billion (Q4 2025), $998.5 million (Q3 2025), and $873.8 million (Q2 2025).